Strategy of long-term anti-HBV treatment after liver transplantation for patients with HBV related liver disease
10.3760/cma.j.cn113855-20221129-00741
- VernacularTitle:乙型肝炎病毒背景肝移植患者术后长期抗乙型肝炎病毒治疗的策略研究
- Author:
Changkun ZHANG
1
;
Jie GAO
;
Yang WANG
;
Xinyu LI
;
Jiye ZHU
;
Xisheng LENG
;
Lei HUANG
Author Information
1. 北京大学人民医院肝胆外科，北京 100044
- Keywords:
Liver transplantation;
Hepatitis B virus;
cccDNA
- From:
Chinese Journal of General Surgery
2023;38(6):435-440
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the risk of HBV recurrence after liver transplantation in patients with end-stage hepatitis B related liver disease, and to explore the indications for antiviral therapy withdrawal.Methods:The data of HBV DNA, cccDNA in liver puncture tissues and peripheral blood in 31 patients after liver transplantation was retrospectively analyzed.Results:Among the 31 patients, 15 (48%) had detectable and quantified HBV DNA in liver biopsy tissue, while their HBV related serological indicators were negative, suggesting an occult HBV infection in some patients. The study found 15 out of 19 cases who were taking Entecavir were cccDNA negative (78.9%), compared to 5 out of 12 cases (41.6%) in Lamivudine regiment ( P=0.03). Conclusions:Hidden HBV infection can be detected by amplifying cccDNA and HBV DNA in liver puncture tissue by using ddPCR. Entecavir is superior to lamivudine in the clearance of cccDNA.
